References
- Arcellx . Arcellx and Kite Announce Expansion in Strategic Partnership (2023). https://ir.arcellx.com/news/news-details/2023/ARCELLX-AND-KITE-ANNOUNCE-EXPANSION-IN-STRATEGIC-PARTNERSHIP/default.aspx
- bit.bio . New collaboration to develop multi-cell models of the human brain (2023). www.bit.bio/news/kcl-collaboration-multi-cell-models-of-human-brain
- Kyverna Therapeutics . Kyverna Therapeutics Announces Collaboration with Charité to Fund Research into B-Cell and Plasma Cell-Targeting Therapies in Patients with Autoimmune Diseases (2023). https://kyvernatx.com/press-releases/kyverna-therapeutics-announces-collaboration-with-charite-to-fund-research-into-b-cell-and-plasma-cell-targeting-therapies-in-patients-with-autoimmune-diseases/
- AstraZeneca . AstraZeneca announces collaboration and investment agreement with Cellectis to accelerate cell therapy and genomic medicine ambitions (2023). www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-cell-and-gene-therapy-deal-w-cellectis.html
- Legend Biotech . Legend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies Targeting DLL3 (2023). https://legendbiotech.com/legend-news/legend-biotech-announces-exclusive-global-license-agreement-for-certain-car-t-therapies-targeting-dll3/
- NCT05680922 . DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects with Extensive Stage Small Cell Lung Cancer (2023). https://classic.clinicaltrials.gov/ct2/show/NCT05680922
- Heartseed . Heartseed Succeeds in Stable Production of High Purity Cardiomyocytes Using iPS Cells from I Peace, A Major Step Forward in Advancing Autologous Cardiac Regenerative Medicine (2023). https://heartseed.jp/en/news/heartseed-succeeds-in-stable-production-of-high-purity-cardiomyocytes-using-ips-cells-from-i-peace-a.html
- Kyverna Therapeutics . Kyverna Therapeutics Announces Publication in The Lancet Neurology of Case Report of Patient with Refractory Myasthenia Gravis Treated with Investigational KYV-101 (2023). https://kyvernatx.com/press-releases/kyverna-therapeutics-announces-publication-in-the-lancet-neurology-of-case-report-of-patient-with-refractory-myasthenia-gravis-treated-with-investigational-kyv-101kyverna-therapeutics-announces-public/
- Haghikia A , HegelmeierT, WolleschakDet al. Anti-CD19 CAR T cells for refractory myasthenia gravis (2023). Lancet Neurol.22, 1104–1105 (2023).
- Atara Biotherapeutics . Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis (2023). https://investors.atarabio.com/news-events/press-releases/detail/330/atara-biotherapeutics-announces-primary-analysis-data-from
- NCT03283826 . Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects with Progressive Multiple Sclerosis (2023). https://clinicaltrials.gov/study/NCT03283826
- NCT03818737 . Multicenter Trial of Stem Cell Therapy for Osteoarthritis (MILES) (2023). https://classic.clinicaltrials.gov/ct2/show/NCT03818737
- Mautner K , GottschalkM, BodenSDet al. Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nat. Med.29, 3120–3126 (2023).
- InGeneron . InGeneron Announces Encouraging Results from Emory University’s 480-Patient Phase III Knee Osteoarthritis Trial (2023).
- MaaT Pharma . MaaT Pharma Announces First Patient Dosed in Phase 2b Randomized Clinical Trial Evaluating MaaT033 in Patients Receiving Allo-HSCT (2023). www.maatpharma.com/november-6-2023-maat-pharma-announces-first-patient-dosed-in-phase-2b-randomized-clinical-trial-evaluating-maat033-in-patients-receiving-allo-hsct/
- NCT05762211 . Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial) (2023). https://clinicaltrials.gov/study/NCT05762211
- Carisma Therapeutics . Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte (2023). https://ir.carismatx.com/node/9696/pdf
- Kyverna Therapeutics . Kyverna Therapeutics Announces FDA Clearance of Phase 2 IND for KYV-101, a Fully Human CD19 CAR T-Cell Therapy to Treat Myasthenia Gravis (2023). https://kyvernatx.com/press-releases/kyverna-therapeutics-announces-fda-clearance-of-phase-2-ind-for-kyv-101-a-fully-human-cd19-car-t-cell-therapy-to-treat-myasthenia-gravis/
- NCT06193889 . A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Subjects with Refractory Generalized Myasthenia Gravis (2023). https://clinicaltrials.gov/study/NCT06193889
- NeoImmuneTech . FDA Grants Orphan Drug Designation to NeoImmuneTech’s NT-I7 for the Treatment of Acute Radiation Syndrome (2023). https://neoimmunetech.com/board/view.html?Ncode=b1&number=264&sWord=&n_list=0&page=1
- TC BioPharm . TC BioPharm Announces FDA Clearance of Phase 1B IND for TCB-008 in Acute Myeloid Leukemia (2023). https://ir.tcbiopharm.com/news/press-releases/detail/68/tc-biopharm-announces-fda-clearance-of-phase-1b-ind-for
- Vertex Pharmaceuticals . Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia (2023). https://investors.vrtx.com/node/31211/pdf
- Businesswire . BRAINSTORM CELL ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Brainstorm Cell Therapeutics Inc. and Encourages Investors to Contact the Firm (2023). www.businesswire.com/news/home/20231103675736/en/
- Businesswire . The Law Offices of Frank R. Cruz Announces Investigation of Brainstorm Cell Therapeutics Inc. (BCLI) on Behalf of Investors (2023). www.businesswire.com/news/home/20231103895066/en/
- Businesswire . INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Brainstorm Cell Therapeutics Inc. (BCLI) on Behalf of Investors (2023). www.businesswire.com/news/home/20231106270747/en/
- Businesswire . Brainstorm Cell Therapeutics Inc. (BCS) Investor Notice: Robbins LLP Reminds Investors of Class Action Against Brainstorm Cell Therapeutics Inc. (2023). www.businesswire.com/news/home/20231106585645/en/
- Businesswire . Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Brainstorm Cell Therapeutics Inc. (BCLI) Investors (2023). www.businesswire.com/news/home/20231108354600/en/
- BusinessWire . Mytos Announces $19 M Series A Funding to Automate Human Cell Manufacturing and Further Accelerate Growth (2023). www.businesswire.com/news/home/20231130974909/en/
- Wiggers K . Neuralink, Elon Musk’s brain implant startup, quietly raises an additional $43 M. techcrunch.com (2023). https://techcrunch.com/2023/11/25/neuralink-elon-musks-brain-implant-startup-quietly-raises-an-additional-43m/
- US SEC . Notice of exempt Offering of Securities - amendment (2023). www.sec.gov/Archives/edgar/data/1708503/000170850323000002/xslFormDX01/primary_doc.xml
- Mehrotra D , CameronD. US Lawmakers Ask SEC to Launch Fraud Investigation into Elon Musk (2023). Wired (2023). www.wired.com/story/elon-musk-nerualink-congress-sec-letter/#
- BusinessWire . Vivodyne Announces $38 Million Seed Financing Led by Khosla Ventures to Develop Lab-Grown Human Organs (2023). www.businesswire.com/news/home/20231122325161/en/